Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Cash from Investing Activities (2016 - 2025)

Lexaria Bioscience's Cash from Investing Activities history spans 11 years, with the latest figure at -$5099.0 for Q4 2025.

  • For Q4 2025, Cash from Investing Activities rose 86.51% year-over-year to -$5099.0; the TTM value through Nov 2025 reached -$210314.0, down 12.84%, while the annual FY2025 figure was -$243019.0, 28.85% down from the prior year.
  • Cash from Investing Activities for Q4 2025 was -$5099.0 at Lexaria Bioscience, up from -$157878.0 in the prior quarter.
  • Across five years, Cash from Investing Activities topped out at $270384.0 in Q1 2021 and bottomed at -$157878.0 in Q3 2025.
  • The 5-year median for Cash from Investing Activities is -$36323.0 (2022), against an average of -$29365.9.
  • The largest annual shift saw Cash from Investing Activities surged 27038500.0% in 2021 before it plummeted 2502150.0% in 2022.
  • A 5-year view of Cash from Investing Activities shows it stood at -$58215.0 in 2021, then soared by 40.15% to -$34842.0 in 2022, then fell by 14.88% to -$40026.0 in 2023, then rose by 5.55% to -$37804.0 in 2024, then surged by 86.51% to -$5099.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Cash from Investing Activities are -$5099.0 (Q4 2025), -$157878.0 (Q3 2025), and -$19443.0 (Q2 2025).